DYNAMICURE

Live / Allowed — Published for opposition (as of 31 Mar 2026)

What this means for you

Approved and waiting on proof of use. It will register unless the applicant drops it, and its 08 Mar 2025 filing date already counts against anyone who files later.

Record

Serial number
99074328
Mark type
Design + words
Filed
08 Mar 2025
Published for opposition
31 Mar 2026
Attorney of record
Keith Toms

Goods and services

  • Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of oncological diseases and disorders; Pharmaceutical preparations for the treatment of autoimmune diseases and disorders, autoimmune deficiency; Pharmaceutical preparations for the treatment of genetic disorders; Pharmaceutical preparations for the treatment of metabolic diseases; Pharmaceutical preparations for the treatment of neurodegenerative diseases; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of eye diseases; Pharmaceutical preparations for the treatment of cardiovascular diseases; Diagnostic biomarker reagents for medical purposes; Protein arrays for medical diagnosis purposes; Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; Diagnostic preparations for medical purposes; Pharmaceutical preparations for the treatment of oncological diseases and disorders, autoimmune diseases and disorders, autoimmune deficiency, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, cardiovascular diseases, all of the foregoing excluding treatments and diagnostics for neuromuscular disorders and orphan diseases
  • Class 042 — Scientific and technological services: Pharmaceutical research and development; Research and development in the field of biologics, namely, antibodies and peptides for the field of cancer, immunotherapies, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, and cardiovascular diseases; Research and development in the field of pharmaceuticals, biopharmaceuticals, and biotechnologies for the treatment of cancer, immunotherapies, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, and cardiovascular diseases; Research and development in the field of biotechnology; Research and development in the field of laboratory testing, diagnostics, and pharmacogenetics for the treatment of cancer, immunotherapies, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases eye diseases, and cardiovascular diseases; Providing medical and scientific research information; Providing medical and scientific research information in the field of pharmaceutical research and development, biotechnology, and pharmacogenetics with respect to cancer, immunotherapies, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases eye diseases, and cardiovascular diseases; Consulting services in the field of pharmaceutical research and development; Consulting services in the field of biotechnology; Consulting services in the field of pharmacogenetics; Consulting services in the field of pharmaceutical research and development, biotechnology, and pharmacogenetics with respect to cancer, immunotherapies, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases eye diseases, and cardiovascular diseases; Research and development in the fields of oncological diseases and disorders, autoimmune diseases and disorders, autoimmune deficiency, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, cardiovascular diseases, all the foregoing excluding treatments and diagnostics for neuromuscular disorders and orphan diseases

Owner

Prosecution history

  • 31 Mar 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
  • 31 Mar 2026 — PUBLISHED FOR OPPOSITION
  • 25 Mar 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
  • 10 Mar 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
  • 12 Feb 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
  • 11 Feb 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
  • 11 Feb 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
  • 04 Nov 2025 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
  • 04 Nov 2025 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
  • 26 Sept 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
  • 26 Sept 2025 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
  • 26 Sept 2025 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
  • 12 Aug 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
  • 12 Aug 2025 — NON-FINAL ACTION E-MAILED
  • 12 Aug 2025 — NON-FINAL ACTION WRITTEN

View this trademark record on Marksy